Physician profile
Ather Bukhari
NPI 1992798391
$2,579.93
in general payments reported to CMS, 2019-2025
32 companies · $468 in 2025
The $468 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $464 · 2020: $314 · 2021: $323 · 2022: $628 · 2023: $292 · 2024: $89.61 · 2025: $468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $850.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $850.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $661.83 | 2019-2025 | Skyrizi, Rinvoq |
| Takeda Pharmaceuticals U.S.A., INC. | $291.95 | 2019-2025 | Entyvio, Eohilia |
| Boston Scientific Corporation | $253.16 | 2020-2025 | Varithena Administration Pack |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $158.05 | 2019-2023 | Xifaxan |
| Janssen Biotech, INC. | $139.20 | 2019-2025 | Tremfya |
| Fujifilm Healthcare Americas Corporation | $138.35 | 2025 | |
| Nestle Healthcare Nutrition INC. | $97.48 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $70.74 | 2022 | |
| Intercept Pharmaceuticals, INC. | $69.51 | 2019-2023 | Ocaliva |
| Braintree Laboratories, INC. | $68.15 | 2021-2022 | |
| Genzyme Corporation | $55.68 | 2025 | |
| Pfizer INC. | $41.50 | 2019-2022 | |
| Ardelyx, INC. | $40.67 | 2022-2023 | Ibsrela |
| Gilead Sciences, INC. | $40.24 | 2020-2024 | |
| Daiichi Sankyo INC. | $39.33 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $37.99 | 2022-2023 | Rebyota |
| Merck Sharp & Dohme LLC | $37.03 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $34.00 | 2021 | |
| Tersera Therapeutics LLC | $33.04 | 2021-2023 | Xermelo |
| Ironwood Pharmaceuticals, INC | $30.47 | 2019-2021 | |
| Ipsen Biopharmaceuticals, INC | $29.20 | 2025 | Iqirvo |
| Ucb, INC. | $27.90 | 2019-2020 | |
| Shire North American Group INC | $22.46 | 2019 | |
| Novo Nordisk INC | $21.95 | 2025 | Wegovy |
| Vivus LLC | $21.38 | 2025 | Pancreaze |
| Regeneron Healthcare Solutions, INC. | $21.35 | 2022 | |
| Celgene Corporation | $19.44 | 2023 | Zeposia |
| Medtronic, INC. | $19.17 | 2023 | Nexpowder |
| Phathom Pharmaceuticals, INC. | $17.77 | 2025 | Voquezna |
| Alfasigma USA, INC. | $15.14 | 2020 | |
| Shield Therapeutics INC | $13.62 | 2024 | |
| Shionogi INC | $12.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ather Bukhari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.